Treatment of patients with chronic hepatitis B with adefovir dipivoxil

Seminars in Liver Disease

Volumn 24, Issue SUPPL. 1, 2004, Pages 37-44

  Tong, Myron J ^a   Tu, Stanley S ^a  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; HBeAg negative; HBeAg positive; Lamivudine; Lamivudine resistant YMDD mutant

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; DNA POLYMERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; PEPTIDE DERIVATIVE; TYROSYLMETHIONYLASPARTYLASPARTIC ACID; UNCLASSIFIED DRUG; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; VIRUS MUTANT; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MUTATION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 2942560781     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828677     Document Type: Conference Paper

References (15)

1. Hepatitis B. Fact sheet WHO/204. Geneva: World Health Organization; October 2000. www.who.int/inffs/en/fact204.htm; accessed on October 13, 2003
2. Manns MP. Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis 2002;22:7-13
3. Manesis EK, Hadziyannis SJ. Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-109
4. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003;23:81-88
5. Perrillo RP, Schiff ER, Davis GL, et al. A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301
6. Niederau C, Heintges T, Lange S, et al. Long term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427
7. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
8. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68
9. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117
10. Heathcote EJ, Jeffers L, Wright T, et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. Hepatology 1998;28(Suppl):317A
11. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816
12. Hadziyannis SJ, Nicolaos CT, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807
13. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis. Hepatology 2002;36(Suppl 2):374A
14. Westland CE, Yang H, Delaney WE IV, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003;38:96-103
15. Xiong S, Yang H, Westland CE, et al. Resistance surveillance of HBeAg-chronic hepatitis B patients treated for two years with adefovir dipivoxil. J Hepatol 2003;38(Suppl 2):628A